Clinical Trial Update: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of CRLX101 in combination with Bevacizumab for recurrent ovarian, fallopian tube, or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CRLX101

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED